Promiscuous translocations into igh switch regions

The genetic hallmark of multiple myeloma

Peter Leif Bergsagel, Marta Chesi, L. A. Brents, W. M. Kuehl

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dysregulation of oncogenes by translocation into the IgH locus at 14q32.3 is a critical event in many B cell malignancies. Based on the site of the breakpoint (JH vs. switch region), the translocations are thought to occur during either VDJ or isotype switch recombination. In multiple myeloma (MM) translocations at 14q32.3 have been reported with variable frequency (20-40%). The other partner has been identified rarely, but includes bcl-1 (25%), bcl-2 (5%), and c-myc (<5%). Hypothesizing that translocations are mediated by errors in IgH switch recombination in MM, we developed a Southern blot assay to distinguish switch recombinations as either legitimate (i.e. occurring between two switch regions) or not, postulating that an iilegitimate switch recombination site represents a potential translocation breakpoint. In 12/13 human myeloma cell lines we identified an illegitimate switch recombination site. We have cloned six of these, and they are all translocation breakpoints involving 14q32: 4pl3, 6?, two 1 Iql3, 16q24, and 21?. In two lines that over-express cyclin Dl, chromosome 11 telomeric to the bcl-1 locus is translocated into a SY region. Interestingly, a karyotypically identifiable t(l 1 ;14)(ql3;q32) is present in only one of these two cell lines. We are in the process of cloning the remainder of the breakpoints, determining the partner chromosomes involved, and the identity of the genes dysrcgulated. Thus it appears that a translocation to an IgH switch site is a common event in MM, and is consistent with the hypothesis that MM cells correspond to a long-lived plasma cell that has undergone IgH switch recombination as it passes from a germinal center to the bone marrow. Identification of the various partner chromosomes involved in 14q32 translocations and of the dysregulated oncogenes should further our understanding of the pathogenesis of myeloma.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume44
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

Multiple Myeloma
Genetic Recombination
Switches
Chromosomes
Oncogenes
Cells
Cell Line
Chromosomes, Human, Pair 11
Cyclins
Germinal Center
Southern Blotting
Plasma Cells
Organism Cloning
B-Lymphocytes
Cloning
Bone Marrow
Assays
Bone
Genes
Plasmas

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Promiscuous translocations into igh switch regions : The genetic hallmark of multiple myeloma. / Bergsagel, Peter Leif; Chesi, Marta; Brents, L. A.; Kuehl, W. M.

In: Journal of Investigative Medicine, Vol. 44, No. 3, 1996.

Research output: Contribution to journalArticle

@article{3e85daa492cb4770818af35775c0e0ad,
title = "Promiscuous translocations into igh switch regions: The genetic hallmark of multiple myeloma",
abstract = "Dysregulation of oncogenes by translocation into the IgH locus at 14q32.3 is a critical event in many B cell malignancies. Based on the site of the breakpoint (JH vs. switch region), the translocations are thought to occur during either VDJ or isotype switch recombination. In multiple myeloma (MM) translocations at 14q32.3 have been reported with variable frequency (20-40{\%}). The other partner has been identified rarely, but includes bcl-1 (25{\%}), bcl-2 (5{\%}), and c-myc (<5{\%}). Hypothesizing that translocations are mediated by errors in IgH switch recombination in MM, we developed a Southern blot assay to distinguish switch recombinations as either legitimate (i.e. occurring between two switch regions) or not, postulating that an iilegitimate switch recombination site represents a potential translocation breakpoint. In 12/13 human myeloma cell lines we identified an illegitimate switch recombination site. We have cloned six of these, and they are all translocation breakpoints involving 14q32: 4pl3, 6?, two 1 Iql3, 16q24, and 21?. In two lines that over-express cyclin Dl, chromosome 11 telomeric to the bcl-1 locus is translocated into a SY region. Interestingly, a karyotypically identifiable t(l 1 ;14)(ql3;q32) is present in only one of these two cell lines. We are in the process of cloning the remainder of the breakpoints, determining the partner chromosomes involved, and the identity of the genes dysrcgulated. Thus it appears that a translocation to an IgH switch site is a common event in MM, and is consistent with the hypothesis that MM cells correspond to a long-lived plasma cell that has undergone IgH switch recombination as it passes from a germinal center to the bone marrow. Identification of the various partner chromosomes involved in 14q32 translocations and of the dysregulated oncogenes should further our understanding of the pathogenesis of myeloma.",
author = "Bergsagel, {Peter Leif} and Marta Chesi and Brents, {L. A.} and Kuehl, {W. M.}",
year = "1996",
language = "English (US)",
volume = "44",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Promiscuous translocations into igh switch regions

T2 - The genetic hallmark of multiple myeloma

AU - Bergsagel, Peter Leif

AU - Chesi, Marta

AU - Brents, L. A.

AU - Kuehl, W. M.

PY - 1996

Y1 - 1996

N2 - Dysregulation of oncogenes by translocation into the IgH locus at 14q32.3 is a critical event in many B cell malignancies. Based on the site of the breakpoint (JH vs. switch region), the translocations are thought to occur during either VDJ or isotype switch recombination. In multiple myeloma (MM) translocations at 14q32.3 have been reported with variable frequency (20-40%). The other partner has been identified rarely, but includes bcl-1 (25%), bcl-2 (5%), and c-myc (<5%). Hypothesizing that translocations are mediated by errors in IgH switch recombination in MM, we developed a Southern blot assay to distinguish switch recombinations as either legitimate (i.e. occurring between two switch regions) or not, postulating that an iilegitimate switch recombination site represents a potential translocation breakpoint. In 12/13 human myeloma cell lines we identified an illegitimate switch recombination site. We have cloned six of these, and they are all translocation breakpoints involving 14q32: 4pl3, 6?, two 1 Iql3, 16q24, and 21?. In two lines that over-express cyclin Dl, chromosome 11 telomeric to the bcl-1 locus is translocated into a SY region. Interestingly, a karyotypically identifiable t(l 1 ;14)(ql3;q32) is present in only one of these two cell lines. We are in the process of cloning the remainder of the breakpoints, determining the partner chromosomes involved, and the identity of the genes dysrcgulated. Thus it appears that a translocation to an IgH switch site is a common event in MM, and is consistent with the hypothesis that MM cells correspond to a long-lived plasma cell that has undergone IgH switch recombination as it passes from a germinal center to the bone marrow. Identification of the various partner chromosomes involved in 14q32 translocations and of the dysregulated oncogenes should further our understanding of the pathogenesis of myeloma.

AB - Dysregulation of oncogenes by translocation into the IgH locus at 14q32.3 is a critical event in many B cell malignancies. Based on the site of the breakpoint (JH vs. switch region), the translocations are thought to occur during either VDJ or isotype switch recombination. In multiple myeloma (MM) translocations at 14q32.3 have been reported with variable frequency (20-40%). The other partner has been identified rarely, but includes bcl-1 (25%), bcl-2 (5%), and c-myc (<5%). Hypothesizing that translocations are mediated by errors in IgH switch recombination in MM, we developed a Southern blot assay to distinguish switch recombinations as either legitimate (i.e. occurring between two switch regions) or not, postulating that an iilegitimate switch recombination site represents a potential translocation breakpoint. In 12/13 human myeloma cell lines we identified an illegitimate switch recombination site. We have cloned six of these, and they are all translocation breakpoints involving 14q32: 4pl3, 6?, two 1 Iql3, 16q24, and 21?. In two lines that over-express cyclin Dl, chromosome 11 telomeric to the bcl-1 locus is translocated into a SY region. Interestingly, a karyotypically identifiable t(l 1 ;14)(ql3;q32) is present in only one of these two cell lines. We are in the process of cloning the remainder of the breakpoints, determining the partner chromosomes involved, and the identity of the genes dysrcgulated. Thus it appears that a translocation to an IgH switch site is a common event in MM, and is consistent with the hypothesis that MM cells correspond to a long-lived plasma cell that has undergone IgH switch recombination as it passes from a germinal center to the bone marrow. Identification of the various partner chromosomes involved in 14q32 translocations and of the dysregulated oncogenes should further our understanding of the pathogenesis of myeloma.

UR - http://www.scopus.com/inward/record.url?scp=33749444470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749444470&partnerID=8YFLogxK

M3 - Article

VL - 44

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 3

ER -